A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)
- 15 August 2002
- journal article
- clinical trial
- Published by Springer Nature in Annals of Hematology
- Vol. 81 (8) , 424-429
- https://doi.org/10.1007/s00277-002-0495-y
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: